CANSINOBIO: COVID-19 mRNA Vaccine was approved by FDA in clinical trials

CANSINOBIO announced on the Hong Kong Stock Exchange that the novel coronavirus mRNA vaccine developed by the Group has been approved by the SDA for drug clinical trials. The results of preclinical studies show that the vaccine can induce high titers of neutralizing antibodies against a variety of important variants identified by the World Health Organization (including current epidemic strains). Compared with the existing COVID-19 vaccine based on the prototype strain, it has a stronger broad spectrum and can more effectively protect the body from the infection of the existing mutants.